The COVID-19 vaccine test has been shown to be safe and capable of eliciting an immune response.

Results in the first phase of clinical trials of a vaccine to combat coronavirus have proven to be safe, tolerated by patients and capable of generating an immune response against the SARS-CoV-2 virus.

The Beijing Biotechnology Institute in China is responsible for this clinical trial and has published its results in the scientific journal ‘The Lancet’.

The study has included 108 healthy adults between the ages of 18 and 60 and has shown “Encouraging results” after 28 days. However, they have indicated that more trials are needed to see if the immune response that directly protects against the virus can last long. Remember that immunity to diseases is usually one year and up to two in certain cases.

“These results represent an important milestone”, notes Wei Chen of the Beijing Institute of Biotechnology,

This trial demonstrates that a single dose of the new vaccine, which uses an adenovirus type 5 vector (Ad5-nCoV), produces in 14 days specific antibodies against the virus and T cells, a type of white blood cell that plays a key role in immune response.

This has made her the potential candidate for further research, but Chen cautions that these results should be interpreted with caution. Just because the vaccine can trigger an immune response doesn’t necessarily mean it will protect humans from the disease.

“This result shows a promising vision for the development of the vaccine, but we are still a long way from making it available to everyoneChen stresses.

Those who volunteered did not present serious symptoms in the 28 days after vaccination, and those who reported some symptoms were moderate.

Common reactions were mild pain, fever, fatigue, headache, and muscle pain.

All the groups of volunteers presented some level of immune response in the form of antibodies that bind to the coronavirus but not necessarily attack it, other participants presented detestable neutralizing antibodies against SARS-CoV-2.

Most groups showed a 4-fold increase in binding antibodies, and just over half of all showed neutralizing antibodies against the virus. Rapid T-cell stimulation was perceived in most of the volunteers.

One of the main limitations of the trial is the size of the group and the duration of the investigation, according to the authors. This limits the ability to detect rarer adverse reactions to the vaccine and also to provide stronger evidence of its ability to generate an immune reaction.

In Wuhan, the epicenter of the pandemic, phase 2 of the trial has already started to determine if the reproduced results show an adverse event up to 6 months after vaccination.

The new trial already involves 500 healthy adults: 250 volunteers who were given a medium dose, 125 who were given a low dose and another 125 who were injected with a placebo to be the control group.

This time, people over 60 years of age who are the main interest group of scientists were allowed access to the experiment for the vaccine to work.

Like the Beijing Institute of Biotechnology, Modern Biopharmaceuticals has reported that He has also found positive results from his first phase vaccine, which they indicate is potential to prevent COVID-19 disease in humans.

It is still a few months before the vaccines give entirely satisfactory results for the organisms that regulate them and their circulation can be given the green light, but these advances give us hope that the virus may be defeated in the future. Share this good news. We are close to hug again without fear.